home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
support.isiresearchsoft.com
/
support.isiresearchsoft.com.zip
/
support.isiresearchsoft.com
/
RefMan
/
capture
/
stndwpi.txt
< prev
next >
Wrap
Text File
|
1999-09-02
|
4KB
|
96 lines
<TITLE>STN-WPINDEX</A> [<I>STN-WPINDEX</I>] </TITLE><PRE>
L6 ANSWER 1 OF 25 COPYRIGHT 1993 DERWENT
AN 92-414996 [50] WPINDEX
DNC C92-184183
TI Treating panic disorders - by nasally administering midazolam in
pharmaceutically acceptable salt carrier.
DC B02
IN SCHWEIZER, E E
PA (UYPE-N) UNIV PENNSYLVANIA
CYC 1
PI US 5166202 A 921124 (9250)* 6 pp A01N043-62
<--
ADT US 5166202 A Cont of US 90-584761 900919, US 91-809205 911213
PRAI US 90-584761 900919; US 91-809205 911213
IC ICM A01N043-62
AB US 5166202 A UPAB: 931116
Use of midazolam (8-chloro-6-(2-fluorophenyl) -1-methyl--4H-
imidazo(1,5-a)(1,4)benzodiazepine) (I) or its salt, nasally, to
treat panic disorder and to treat and prevent panic attacks is new.
USE/ADVANTAGE - The sedative (I) is useful for the treatment
of panic disorder and the treatment, control and prevention of
panic attacks. Nasal admin. is convenient and ensures rapid onset
of action with reductions in overall panic attack frequency and
interepisode levels of non-panic anxiety. It shows no rebound
effect, euphonic effect or tolerance. Admin. is nasal, pref. as a
nasal spray at a daily dose of 0.25-5 mg in single or divided
doses. Of 5 patients treated with (I) for 3 weeks, 4 reported
reduction or complete blockade of panic attacks.
Dwg.0/0
FS CPI
FA AB
MC CPI: B06-D17; B12-C08; B12-C10
L6 ANSWER 4 OF 25 COPYRIGHT 1993 DERWENT
AN 91-355678 [49] WPINDEX
CR 92-233975 [28]
DNN N91-272224 DNC C91-153287
TI New 1-(1-phenyl cyclohexyl)-piperidine and -piperazine derivs. -
used as tracers for phencyclidine in fluorescence polarisation
immunoassay.
DC B03 B04 S03
IN DUBLER, R E; FRINTNER, M P; GROTE, J; HADLEY, G A; HAWKS-WORTH, D J;
HOPKINS, H D; NAM, D S; UNGEMACH, F S; WRAY, L K
PA (ABBO) ABBOTT LAB
CYC 14
PI EP 459387 A 911204 (9149)*
<--
R: AT BE CH DE ES FR GB IT LI NL
AU 9177272 A 911205 (9205)
CA 2043372 A 911130 (9208)
JP 04235199 A 920824 (9242) 27 pp C07K015-12
US 5155212 A 921013 (9244) 22 pp C07K015-14
EP 459387 A3 920902 (9338)
<--
ADT EP 459387 A EP 91-108674 910528; JP 04235199 A JP 91-125-955 910529;
US 5155212 A CIP of US 86-866193 860521, US 90-529988 900529; EP
459387 A3 EP 91-108674 910528
PRAI US 90-529988 900529
REP NoSR.Pub ; EP 218010; US 4281065; US 4446065
IC ICM C07K015-12; C07K015-14
ICS A61K039-44; C07D211-06; C07D295-02; C07D307-00;C07D311-00;
C07D493-10; C07K013-00; C07K015-16; C07K017-06;C12P021-08;
G01N033-53
AB EP 459387 A UPAB: 930928 Phencyclidene derivs. of formula (I)
or (II) are new. W = CH or N. R = a linking gp. including up to 4
heteroatoms selected from O, N, S, P or F and contg. a total of 0-8
C and heteroatoms, and contg. 0 or 1 aliphatic or aromatic ring
structures. Z = NH, CO or CNH; n = 0 or 1, when W = N; or n = 1, \
when W = CH. Q = poly(aminoacid) or a poly(amino acid) deriv. such as
thyroglobulin. Also claimed is an antibody to (I) or (II). A process
for detecting phencyclidine and/or its metabolites in a sample is claimed,
comprising:- (a) contacting the sample with antibodies and (I) or
(II); (b) passing plane polarised light through the soln. to obtain
a fluorescence polarisation response; and (c) detecting the
fluorescence polarisation response. A kit for this process is
provided.
USE/ADVANTAGE - (I) or (II) are tracers for use with the antibodies
in fluorescence polarisation immunoassays. The cpds. have
detectable fluorescence polarisation and are used to assay
competition between phencyclidine and phencyclidine metabolites and
as tracers for the recognition sites of the antibodies.
Phencyclidine has potent analgesic and anaesthetic properties, and
produces serious and prolonged post-anaesthetic confusion and
delirium.
0/0
FS CPI EPI
FA AB
MC CPI: B04-C01; B05-B01E; B05-B01H; B05-B01J; B05-B01M; B06-A03;
B07-D05; B07-D11; B07-D12; B11-C08D3; B12-K04A
EPI: S03-E14H4
</PRE>